Atezolizumab combined with R-GemOx shows favorable safety and efficacy in relapsed/refractory DLBCL, especially in transformed FL cases. The study reported a 59% overall response rate and a 33% ...
The field of cancer biology has recently recognized the significance of immunogenic cell death (ICD), a process by which dying cells emit alarm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results